Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company found itself mulling whether to sell its consumer health care business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.
Looking for leads, investment insights, or competitive intelligence?
News about Pfizer
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.
Pfizer temporarily backed down on price hikes following Trump's threats.
Trump is pleased with the result of his blast.
Must-read business news, delivered every morning.